WALTHAM, Mass.–(BUSINESS WIRE)–Regenacy Pharmaceuticals, a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, today announced the appointment of David Michelson, M.D., as Chief Medical Officer (CMO). Dr. Michelson has served as Consultant CMO since September 2019.
“I’m very pleased to officially welcome David to Regenacy’s team,” said Simon Jones, Ph.D., Regenacy’s President and Chief Executive Officer. “For the past 7 months, David’s drug development expertise has been invaluable. He provided tremendous contributions and perspectives on our development strategy for ricolinostat as a consultant, and our team looks forward to continuing to work with him.”
“Regenacy is pursuing a novel approach to restoring nerve function that addresses a critical unmet need of patients with peripheral neuropathy,” said Dr. Michelson. “It has been a pleasure working alongside Regenacy’s tenured leadership team over the last several months and I look forward to applying my drug development experience to advance ricolinostat into the clinic for DPN.”
Dr. Michelson brings over 24 years of industry experience to Regenacy. Prior to joining the company, he served as CMO for Proclara Biosciences where he oversaw multiple Phase 1 studies for a program targeting amyloidosis. Before Proclara, he worked at Merck for 11 years as the Neuroscience Therapeutic Area Head and Vice President for Clinical Development. Dr. Michelson began his career at Eli Lilly and Company, where he held positions of increasing responsibility for early and late stage drug development. Dr. Michelson earned his M.D. from the Albert Einstein College of Medicine in New York, and completed his residency in psychiatry at Yale University, where he also served as a chief resident and faculty member prior to joining the National Institute of Mental Health as a research physician.
Regenacy Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company regenerating biological function by protein acetylation for the treatment of diabetic and other peripheral neuropathies and other chronic conditions. The company’s selective inhibition technology provides superior safety profiles and potential enhanced efficacy compared to non-selective HDAC inhibitors. Regenacy selectively inhibits histone deacetylase 6 (HDAC6) to restore normal intracellular protein and organelle transport in peripheral neuropathies, and also has a portfolio of selective HDACs 1 and 2 inhibitors that have potential to treat major blood diseases such as leukemia, sickle cell disease, β-thalassemia, and cognitive dysfunction in neurological disorders. www.regenacy.com